key: cord-0712269-7lkrtqwe
authors: Goerlich, Erin; Minhas, Anum; Gilotra, Nisha; Barth, Andreas S.; Mukherjee, Monica; Parziale, Allyson; Wu, Katherine C.; Hays, Allison G.
title: Left atrial function in patients with COVID-19 and its association with incident atrial fibrillation/flutter
date: 2021-05-31
journal: J Am Soc Echocardiogr
DOI: 10.1016/j.echo.2021.05.015
sha: 5c3d5ff4c23ab9a3015be55c40936af39f9855f7
doc_id: 712269
cord_uid: 7lkrtqwe

nan

Abbreviations 2DE = two-dimensional echocardiography AF = atrial fibrillation or atrial flutter ARDS = acute respiratory distress syndrome BMI = body mass index COVID-19 = coronavirus disease 2019 ICU = intensive care unit LA = left atrium LAEF = left atrial emptying fraction LAS = left atrial strain LAVI = left atrial volume index NT-proBNP = N-terminal pro-brain natriuretic peptide J o u r n a l P r e -p r o o f Myocardial injury in Coronavirus disease 2019 (COVID-19) has been associated with adverse outcomes, however associations between myocardial injury and arrhythmias, such as atrial fibrillation/flutter (AF), in this population are not well established. 1, 2 Recent advances in twodimensional echocardiography (2DE), including speckle-based strain, enable the quantification of left atrial (LA) strain, a measure of atrial deformation that has previously been shown to be predictive of AF and cardiovascular events in stable outpatients. 3 p<0.001) compared to controls. Traditional cardiovascular risk factors, inflammatory and cardiac biomarkers, and mortality were similar between groups, however there was a higher incidence of intensive care unit (ICU) admission and lower incidence of acute respiratory distress syndrome (ARDS) in the control group (Table 1A) .

COVID-19 patients who developed AF (n=24; 30%) had higher troponin I, N-terminal pro-B type natriuretic peptide (NT-proBNP), ICU admission, ARDS, and shock; they were overall older and more often Caucasian compared to COVID-19 patients without AF (Table 1B) troponin and NT-proBNP levels were not. These findings persisted on multivariable regression adjusted for age, sex, and body mass index (Supplemental Table 1 ).

These findings show that hospitalized COVID-19 patients have reduced LA function compared to COVID-19-negative controls with similar degree of critical illness, and this dysfunction is more pronounced in COVID-19 patients who develop atrial fibrillation or flutter. Importantly, J o u r n a l P r e -p r o o f we report an independent association between LAS and AF among COVID-19 patients, even after adjustment for confounders.

Myocardial injury via serum and echocardiographic findings is associated with AF in the present COVID-19 population studied. Associations between AF and inflammatory markers such as Creactive protein in COVID-19 have been reported. 2 We found an insignificant trend towards higher inflammatory markers in COVID-19 patients compared to controls which was not associated with AF. The observation of more incident AF in patients with higher troponin and NT-proBNP levels, which are associated with worse outcomes in COVID-19, supports hypotheses involving COVID-19-related myocardial injury beyond that of generalized critical illness. 1 LAVI was lower in COVID-19 patients compared to controls and similar in COVID-19 patients with and without AF, suggesting that LA dysfunction developed acutely rather than in the setting of chronic remodeling. Both LAVI and LAS have been shown to predict AF and cardiovascular outcomes in the outpatient setting. 4 The association of reduced LAS with AF in COVID-19

suggests that LAS may have greater utility than LAVI in identifying atrial injury in this population. Furthermore, reduced LAS may represent a higher-risk COVID-19 phenotype that warrants closer monitoring for cardiac complications, including AF.

Limitations to our study include modest sample size, cross-sectional design, and dependence on 2DE image quality which allowed for LAS measurement in the 2-chamber or 4-chamber apical view. Since it is not routinely measured, baseline LAS remains unknown, and causality cannot J o u r n a l P r e -p r o o f 6 be inferred based on cross-sectional design. ARDS was less frequent in the control group, however when this was adjusted for, LAS remained significantly associated with AF (p<0.001).

Despite excluding patients with history of AF, prior undiagnosed paroxysmal AF remains a potential confounder. Lastly, findings here may only apply to COVID-19 inpatients.

Systemic inflammation in COVID-19 may contribute to an atrial myopathy that leads to increased risk of atrial arrhythmias. Evaluation of LA mechanics by 2DE provides useful data for risk stratification. Further studies are needed to confirm these findings in larger populations and define underlying mechanisms.

J o u r n a l P r e -p r o o f Table 1 

Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection

Atrial Arrhythmias in COVID-19 Patients

Low Left Atrial Strain Is Associated With Adverse Outcomes in Hypertrophic Cardiomyopathy Patients

New echocardiographic techniques for evaluation of left atrial mechanics

ASE Statement on Protection of Patients and Echocardiography Service Providers During the 2019 Novel Coronavirus Outbreak: Endorsed by the American College of Cardiology

Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary